Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Reid Thompson, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00592709
First received: January 2, 2008
Last updated: June 14, 2013
Last verified: June 2013
  Purpose

We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis, looking for unique protein signatures.


Condition
Brain Diseases

Study Type: Observational
Official Title: Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Biospecimen Retention:   Samples With DNA

Brain Tissue


Estimated Enrollment: 150
Study Start Date: May 2003
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:

We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis. Data from different brain tissues including tumors of different histological sub-types will be analyzed for unique protein signatures. These protein signatures will then be statistically correlated with clinical data including time to tumor progression and response to therapy.

The goal of this study is to determine molecular patterns that will be more predictive of tumor behavior, thus leading to an improved understanding of the basic biology of these poorly understood cancers. This in turn, may lead to more refined therapies and improved outcomes.

  Eligibility

Ages Eligible for Study:   2 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Age 2 years through Age 85 years old

Criteria

Inclusion Criteria:

  • A diagnosis of brain tumor or other non-cancerous tissue and are considered candidates fro a surgical procedure to biopsy or remove the brain tumor or other tissue type at Vanderbilt University Medical Center.
  • Age 2 to 85

Exclusion Criteria:

  • Patient or guardian that is unable to understand the informed consent process.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00592709

Locations
United States, Tennessee
Vanderbilt University Medical Center, Department of Neurological Surgery
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Reid C. Thompson, MD Vanderbilt University Medical Center, Department of Neurological Surgery
  More Information

No publications provided

Responsible Party: Reid Thompson, Professor of Neurological Surgery, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00592709     History of Changes
Other Study ID Numbers: 030258
Study First Received: January 2, 2008
Last Updated: June 14, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on November 25, 2014